Loading...
Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
Objective: Bococizumab, a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, has been shown to reduce low-density lipoprotein cholesterol (LDL-C). Here, we describe the pharmacokinetics and pharmacodynamics of bococizumab and its effect on lipoprotein particle composition a...
Na minha lista:
| Udgivet i: | Int J Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dustri-Verlag Dr. Karl Feistle
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6862531/ https://ncbi.nlm.nih.gov/pubmed/31549625 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5414/CP203418 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|